Repositioning Candidate Details
| Candidate ID: | R0352 |
| Source ID: | DB00977 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Ethinylestradiol |
| Synonyms: | 17-ethinyl-3,17-estradiol; 17-ethinyl-3,17-oestradiol; 17-ethinylestradiol; 17alpha-Ethinyl estradiol; 17α-ethynylestradiol; Ethinyl estradiol; Ethinylestradiol; Ethinyloestradiol; Ethynyl estradiol |
| Molecular Formula: | C20H24O2 |
| SMILES: | [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3 |
| Structure: |
|
| DrugBank Description: | Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering. It was developed in an effort to create an estrogen with greater oral bioavailability. These properties were achieved by the substitution of an ethinyl group at carbon 17 of . Ethinylestradiol soon replaced in contraceptive pills. Ethinylestradiol was granted FDA approval on 25 June 1943. |
| CAS Number: | 57-63-6 |
| Molecular Weight: | 296.4034 |
| DrugBank Indication: | Ethinylestradiol is combined with other drugs for use as a contraceptive, premenstrual dysphoric disorder, moderate acne, moderate to severe vasomotor symptoms of menopause, prevention of postmenopausal osteoporosis. |
| DrugBank Pharmacology: | Ethinylestradiol is a synthetic estrogen that decreases luteinizing hormone to decrease endometrial vascularization, and decreases gonadotrophic hormone to prevent ovulation. It has a long duration of action as it is taken once daily, and a wide therapeutic index as overdoses are generally not associated with serious adverse effects. Patients should be counselled regarding the risks of thrombotic events. |
| DrugBank MoA: | Ethinylestradiol is a synthetic estrogenic compound. Use of estrogens have a number of effects on the body including reduced bone density. Combined oral contraceptives suppress ovulation by suppressing gonadotrophic hormone, thickening cervical mucus to prevent the travel of sperm, and preventing changes in the endometrium required for implantation of a fertilized egg. Ethinylestradiol decreases luteinizing hormone, decreasing vascularity in the endometrium. It also increases sex hormone binding globulin. |
| Targets: | Estrogen receptor alpha agonist; Nuclear receptor subfamily 1 group I member 2 agonist |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I15 | 1290 | Bone disease | A connective tissue disease that affects the structure or development of bone or causes an impairment of normal bone function. http://en.wikipedia.org/wiki/Bone_disease | disease of anatomical entity/ musculoskeletal system disease/connective tissue disease | Details |